Tuesday, October 4, 2022


Biotechnology News Magazine

Thermo Fisher Scientific Showcases New Clinical and Research Lab Solutions at AACC 2022

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Thermo Fisher Scientific Inc., the world leader in serving science, is showcasing innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics. During the 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022), being held at the McCormick Place Convention Center in Chicago, July 24–28, Thermo Fisher is exhibiting within booth #1413.

“Our latest platform and workflow innovations give clinical laboratories and researchers greater flexibility and assurance as they respond to new and existing diagnostic challenges,” said Gianluca Pettiti, executive vice president, Thermo Fisher Scientific. “By minimizing hands-on time, reducing time-to-results, and improving analytical performance, we’re enabling the science that shapes the future of diagnostics, as we all work toward improving patient outcomes.”

Enabling Clinical Research Lab Agility and Responsiveness

The Applied Biosystems TaqMan-SARS-CoV-2 Mutation Panel* enables labs to build their own custom panel from a menu of verified real-time PCR assays. This meets the evolving needs of customers and public health agencies seeking to rapidly identify and survey current mutations as well as emerging variants.

To support labs as they move beyond COVID testing, Thermo Fisher is evolving its respiratory testing menu and improving automation to accelerate research. The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit** helps labs expand their existing COVID-19 testing menu for respiratory samples while maintaining workflow simplicity and without increasing operational costs.

Also featured at AACC is the new Thermo Scientific KingFisher SpeciTRAX Sample Transfer System, which provides researchers in infectious diseases and genetics with an automated sample-handling system, including new features, such as an automated decapper, that relieve the sample processing bottleneck for increased throughput.

A new interface with the Inpeco S.A.’s FlexLab Total Laboratory Automation system (TLA), enables primary tubes on the Inpeco LAS to be transported directly to the Thermo Scientific Cascadion SM Clinical Analyzer*** for automated loading, pre-treatment and analysis. This first-of-its-kind integration enables fully automated, gold-standard LC-MS/MS technology to improve clinical lab productivity.

New Technology and Assays

The Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay*** is now available on medium to high-throughput instruments, including the Indiko Plus and Mindray BS-480, Mindray BA-800M. Labs of any size can now accurately test for multiple drugs of abuse at high volume using fully automated analyzers. Thermo Fisher’s broad and complementary offering of screening to confirmatory solutions also includes the Thermo Scientific Tox Explorer Collection, an all-in-one LC-MS/MS solution for toxicology.

Enhanced Allergy and Autoimmune Testing

The Thermo Scientific EliA RNA Pol III and EliA Rib-P*** tests have received U.S. FDA clearance for aiding in the diagnosis of Systemic Sclerosis and Systemic Lupus Erythematosus. These tests are part of a broader EliA portfolio of connective tissue disease tests that help provide a clearer clinical picture for patients.

*The Applied Biosystems Taqman-SARS-CoV-2 Mutation Panel and Thermo Scientific KingFisher SpeciTRAX Sample Transfer System are “For Research Use Only. Not for use in diagnostic procedures.”

**The Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit is “For Emergency Use Authorization (EUA) Only. For prescription use only. For in vitro diagnostic use.”

***The Thermo Scientific Cascadion SM Clinical Analyzer, the Thermo Scientific DRI Fentanyl II Drugs of Abuse Assay and the Thermo Scientific EliA RNA Pol III and EliA Rib-P are “For In Vitro Diagnostic Use.”

Workshops at AACC

Thermo Fisher is hosting multiple workshops during AACC designed to give attendees more in-depth information on the applications and benefits of its advanced solutions.

Thinking Beyond the Test workshop is a workshop that broadly discusses the role of clinical laboratories in impacting patient care. The workshop is on Tuesday, July 26 from 7:00 a.m. to 8:30 a.m. in Regency Ballroom B. Register here.

MAS Controls – Ortho VITROS Users Group Meeting features a discussion on how Thermo Scientific MAS Quality Controls – using LabLink software on Ortho VITROS platforms – can help enhance productivity, improve clinical outcomes and reduce costs. The workshop is on Tuesday, July 26 from 7:00 a.m. to 8:30 a.m. in Regency C and D. Register here.

LC-MS/MS as a First Line Screening Assay workshop will discuss how the use of LC-MS/MS for early diagnosis is imperative for early treatment and disease prevention. The workshop is on Wednesday, July 27 from 7:00 a.m. to 8:30 a.m. in Regency Ballroom E. Register here.

From COVID-19 and Beyond workshop covers the benefits of PCR and multiplex testing as the industry moves beyond COVID. This workshop is on Wednesday, July 27, from 7:00 a.m. to 8:30 a.m. in  Regency Ballroom C. Register here.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine